Key answers to common questions
Is Suboxone a Schedule II drug?
No. Buprenorphine, including Suboxone, is in Schedule III.
Full opioids such as fentanyl, oxycodone, and methadone are in Schedule II, according to the DEA.
Is it illegal to have Suboxone without a prescription?
Buprenorphine is a federally controlled substance that is meant to be used only with a valid prescription, and the FDA label warns that it is subject to criminal diversion.
If you are using buprenorphine you got from someone else, a prescriber can help you get legal, monitored treatment.
Is Suboxone the same as Subutex?
Both contain buprenorphine and both are Schedule III.
Suboxone also contains naloxone, which is added to discourage misuse. The DEA lists Subutex as a buprenorphine trade name, and buprenorphine-only tablets are available as generics.
Suboxone is a controlled substance. Its active ingredient, buprenorphine, is listed in Schedule III of the federal Controlled Substances Act, a category the DEA describes as having a moderate to low potential for physical and psychological dependence.
Being “controlled” does not mean Suboxone is dangerous to take as prescribed. It means federal law sets rules for who can prescribe it, how it is dispensed, and how it must be stored and tracked. Those rules exist because buprenorphine is an opioid and can be misused.
This guide covers Suboxone’s DEA schedule, whether it counts as a narcotic, how it can be misused, what it looks like, overdose risks, and how prescribing rules changed in 2023. It does not cover dosing, which should only come from your prescriber.
What schedule is Suboxone?
Suboxone is a Schedule III controlled substance.
Federal regulations list buprenorphine in Schedule III, and the DEA states that buprenorphine and all products containing buprenorphine are controlled in that schedule, including Suboxone, Subutex, and generics.
The federal schedules are set out in the Code of Federal Regulations. Section 1308.13 lists buprenorphine under the narcotic drugs section of Schedule III. The DEA’s buprenorphine fact sheet confirms that buprenorphine and all products containing buprenorphine are controlled in schedule III. It also notes that buprenorphine was moved from Schedule V to Schedule III in 2002, when the FDA approved Suboxone and Subutex for opioid use disorder.
The FDA prescribing information for Suboxone film says the same, describing buprenorphine as a Schedule III controlled substance that can be abused in a manner similar to other opioids.
What does Schedule III mean?
The DEA groups controlled drugs into five schedules based on medical use and potential for misuse or dependence. According to the DEA, Schedule III drugs have a moderate to low potential for physical and psychological dependence, with misuse potential lower than Schedule I and II but higher than Schedule IV.
| Schedule | DEA description | Examples named by the DEA |
|---|---|---|
| Schedule I | No currently accepted medical use, high potential for abuse | Heroin, LSD, ecstasy |
| Schedule II | High potential for abuse, may lead to severe dependence | Fentanyl, oxycodone, methadone |
| Schedule III | Moderate to low potential for dependence | Ketamine, anabolic steroids, Tylenol with codeine (buprenorphine is also listed here in federal regulations) |
| Schedule IV | Low potential for abuse and dependence | Xanax, Valium, tramadol |
| Schedule V | Lower potential for abuse than Schedule IV | Certain cough medicines with codeine, Lyrica |
U.S. buprenorphine prescriptions dispensed
Prescriptions for buprenorphine products roughly tripled, from 6.3 million in 2010 to 18.3 million in 2025.

Is Suboxone a narcotic?
Suboxone is a narcotic in the legal sense, because federal regulations classify buprenorphine among the “narcotic drugs” in Schedule III.
Medically, the more precise term is opioid. Buprenorphine is a partial opioid agonist, which works differently from full opioids like heroin or fentanyl.
“Narcotic” is mainly a legal and law enforcement word. In the federal schedules, buprenorphine appears under the heading “narcotic drugs,” and the DEA fact sheet compares it with other narcotic drugs. Health agencies such as NIDA and SAMHSA generally use the word “opioid” instead.
The medical difference matters. SAMHSA explains that buprenorphine is an opioid partial agonist whose effects, such as euphoria and slowed breathing, are weaker than full opioid agonists such as methadone and heroin. So while the legal label groups it with other narcotics, it behaves differently in the body. Our guide on how Suboxone works explains the partial agonist effect in more detail.

Can Suboxone be misused?
Suboxone can be misused, which is one reason buprenorphine is a controlled substance.
Buprenorphine can produce euphoria, especially in people who do not use opioids regularly, and it has been misused by swallowing, snorting, and injecting.
The DEA reports that buprenorphine has been misused through various routes of administration, including under the tongue, in the nose, and by injection, both as a heroin substitute and as a primary drug of misuse. NIDA notes that people without opioid use disorder could get a high from buprenorphine, but that most people who misuse buprenorphine do so to control withdrawal symptoms from other opioids, not to get high.
Naloxone is added to Suboxone to make misuse less appealing. SAMHSA states that naloxone is added to decrease the likelihood of diversion and misuse. Signs that use has moved beyond a prescription can include:
- Taking more than prescribed or running out early.
- Using buprenorphine that was not prescribed to you.
- Snorting or injecting it.
- Combining it with alcohol, benzodiazepines, or other drugs to change how it feels.
If any of these sound familiar, it is worth talking honestly with a prescriber. Misuse is a sign that treatment needs adjusting, not a reason to give up on treatment.

What does Suboxone look like?
Brand-name Suboxone is an orange rectangular film with a white printed logo, packaged in child-resistant foil pouches.
Buprenorphine and naloxone also come as generic films and as sublingual tablets, including the brand Zubsolv.
The FDA label describes Suboxone as an orange rectangular film with a white printed logo in child-resistant polyester/foil laminated pouches, made to dissolve under the tongue or inside the cheek. MedlinePlus notes that buprenorphine and naloxone comes as a sublingual tablet (Zubsolv) and as a sublingual film (Suboxone), while buprenorphine alone comes as a sublingual tablet.
Generic films are also available. The FDA’s timeline of opioid-related actions records that in June 2018, the agency approved the first generic versions of Suboxone sublingual film. Generic products may differ in color, shape, and markings from the brand, so the safest way to identify a medicine is to check with a pharmacist.
Other buprenorphine products include extended-release injections such as Sublocade and Brixadi, according to the DEA. Our comparisons of Subutex vs Suboxone and Suboxone vs Sublocade explain how these forms differ.

Can you overdose on Suboxone?
A person can overdose on Suboxone, although buprenorphine causes less breathing suppression at high doses than other opioids.
The risk rises sharply when Suboxone is mixed with alcohol, benzodiazepines, or other sedatives, and in children or people who do not use opioids.
The FDA label lists the signs of buprenorphine overdose as pinpoint pupils, sedation, low blood pressure, low blood sugar, slowed breathing, and death. The label warns that combining buprenorphine with benzodiazepines or other central nervous system depressants, including alcohol, increases the risk of overdose, respiratory depression, and death.
Several groups face higher risk:
- Children. The FDA label states that buprenorphine can cause severe, possibly fatal, breathing problems in children who are accidentally exposed. Keep it locked up, out of sight and reach.
- People who do not use opioids. The label reports deaths among opioid-naive people given buprenorphine for pain.
- People mixing substances. The DEA notes severe respiratory depression can occur, especially when buprenorphine is combined with benzodiazepines.
For context, the DEA fact sheet reports that America’s Poison Centers recorded 3,842 case mentions and 1 death associated with buprenorphine in 2023. Even so, any overdose is an emergency. Signs include extreme sleepiness, slow or stopped breathing, and pinpoint pupils. NIDA advises giving naloxone if available and that people should still call 911 immediately.

What are the rules for prescribing Suboxone?
Suboxone prescribing rules became simpler in 2023.
Congress eliminated the special “X-waiver” in December 2022, so any practitioner with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for opioid use disorder, if state law allows.
The DEA explained in a January 2023 letter to registrants that the Consolidated Appropriations Act of 2023 eliminated the DATA-Waiver program. Prescriptions now only need a standard DEA registration number, and there are no longer federal limits on how many patients a prescriber may treat with buprenorphine.
SAMHSA adds that all practitioners with a current DEA registration that includes Schedule III authority may now prescribe buprenorphine for opioid use disorder if permitted by state law. A separate provision requires new or renewing DEA registrants to complete training on substance use disorders. State rules can still be stricter than federal law.
Buprenorphine use has grown a great deal. The DEA fact sheet, citing IQVIA data, reports that U.S. prescriptions for buprenorphine products rose from about 6.3 million in 2010 to 18.3 million in 2025, with 12.4 million in 2015 and 18.0 million in 2020.
Other federal rules that still apply include:
- A valid prescription is required. Sharing or selling buprenorphine is illegal.
- Buprenorphine for opioid use disorder can be prescribed in regular medical offices, unlike methadone, which NIDA notes is only available through approved opioid treatment programs for this use.
- The DEA reports that telemedicine flexibilities for prescribing controlled medicines, including buprenorphine, have been extended through December 31, 2026.
For more on getting a prescription locally, see our guide to Suboxone treatment in Kentucky.

When should you get help?
You should get help if opioid use is hurting your health, work, or relationships, or if you are using buprenorphine that was not prescribed to you.
A legal prescription with medical oversight and counseling is safer and more effective than self-treating.
Bluegrass Recovery Center in Louisville offers outpatient treatment for opioid use disorder with no overnight stay. Our Suboxone clinic in Louisville provides buprenorphine prescribed and monitored by our medical team, alongside therapy and psychiatric care. Through our medication-assisted treatment program, we also prescribe naltrexone (Vivitrol). We do not prescribe methadone.
Medication works best alongside counseling. You can join our intensive outpatient program, which meets 9 to 12 three or six days a week, or our partial hospitalization program, which meets weekdays 9 to 3 and Saturdays 9 to 2. Lower-intensity outpatient care offers one or two sessions a week. If you are actively using opioids, a doctor may recommend medically supervised withdrawal first.
Learn more about opioid addiction treatment, call admissions 24/7 at (502) 385-4424, or verify your insurance. We accept most major private insurance plans. In an emergency, call 911. If you are in crisis, call or text 988.

Common Questions
Do you need a special doctor to prescribe Suboxone?
Not anymore. Since the X-waiver was eliminated, any practitioner with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for opioid use disorder, as long as state law permits it. Many people still choose an addiction treatment program for the added counseling and support.
Can Suboxone show up on a drug test?
Whether buprenorphine shows up depends on the type of test used. If you have a prescription, tell the testing provider.
